Lyell Immunopharma Cash Flow Statement (2020-2026) | LYEL

Cash Flow Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income (Quarter)
-62.49M-48.89M-47.22M-68.18M-36.31M-64.19M-11.33M-58.06M-60.64M-52.43M-52.42M-48.76M-45.16M-44.54M-196.23M-53.51M-43.86M-33.99M-124.97M-42.07M
Share-based Compensation (Quarter)
15.25M13.04M21.18M22.03M22.41M19.12M18.36M13.88M14.22M10.52M8.46M9.15M8.28M7.62M8.08M6.02M5.00M5.23M25.57M4.29M
Gains from Sales and Divestitures (Quarter)
2.99M3.97M
Gains from Investment Securities (Quarter)
42.18M12.52M36.40M5.00M4.63M0.07M2.92M0.12M0.08M-12.93M
Asset Writedowns and Impairment (Quarter)
36.40M5.00M-5.00M51.30M1.40M
Non-cash Items (Quarter)
23.16M24.40M
Cash from Operations (Quarter)
-33.95M-25.49M-33.21M-47.85M-44.33M-37.10M-40.27M-46.21M-39.16M-37.69M-40.63M-42.02M-38.09M-35.04M-47.24M-54.74M-34.46M-28.58M-32.25M-38.51M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)
-0.40M-0.55M-0.47M-0.47M-0.23M0.43M1.21M1.85M2.08M2.29M3.38M4.37M3.76M3.59M2.96M1.73M1.17M1.01M1.06M0.89M
Depreciation & Amortization (CF) (Quarter)
3.01M4.09M4.57M4.19M4.17M4.62M5.04M5.03M5.06M5.10M5.06M5.02M4.90M4.68M5.03M3.44M3.13M2.57M2.40M2.33M
Change in Working Capital
Change in Account Payables (Quarter)
0.35M-0.99M0.10M2.94M-1.77M0.02M-0.53M2.07M0.38M-1.41M0.42M-0.11M-0.52M-0.57M-2.04M-1.65M-0.23M-0.78M0.33M2.38M
Change in Accured Expenses (Quarter)
3.08M1.94M4.22M-6.39M-0.77M1.32M5.37M-5.86M2.27M4.61M-1.74M-3.61M0.52M3.09M-1.25M-9.79M-3.33M0.57M4.90M-3.57M
Investing Activities
Capital Expenditures (Quarter)
24.45M-38.20M60.07M0.11M16.80M2.79M-18.37M0.40M-0.36M-0.03M0.03M0.03M0.33M0.06M-0.28M0.15M0.26M0.06M0.30M0.09M
Sales of Property, Plant and Equipment (Quarter)
0.02M
Change in Acquisitions & Divestments (Quarter)
200.87M142.04M70.33M79.81M121.85M106.50M110.90M142.25M187.10M178.15M156.12M130.03M161.80M133.41M123.70M154.12M93.52M74.14M52.91M54.65M
Cash from Investing Activities (Quarter)
-39.47M-144.91M-73.86M-26.12M25.02M-57.09M46.65M32.15M152.91M99.67M-100.69M21.99M45.01M1.92M53.51M69.47M12.65M3.35M-31.36M17.38M
Financing Activities
Change in Capital Stock
Shares Issued (Quarter)
391.80M-390.82M-2.04M2.56M-1.67M8.37M-7.73M1.16M-1.16M0.10M0.71M-0.66M-0.15M0.36M0.03M
Shares Repurchased (Quarter)
Preferred Shares Issued (Quarter)
Misc.
Cash from Financing Activities (Quarter)
393.49M-0.53M7.40M2.56M2.46M4.76M0.86M-0.07M1.20M-0.14M0.76M0.03M0.86M0.44M0.00M0.18M50.00M0.22M51.72M
Change in Cash (Quarter)
320.07M-170.94M-99.68M-71.42M-16.86M-89.43M7.24M-14.13M114.95M61.84M-140.57M-20.00M7.78M-33.12M6.70M14.73M-21.63M24.77M-63.39M30.59M
Free Cash Flow (Quarter)
-58.39M12.71M-93.28M-47.96M-61.13M-39.89M-21.90M-46.61M-38.80M-37.66M-40.66M-42.05M-38.42M-35.10M-46.97M-54.89M-34.72M-28.64M-32.55M-38.60M
Net Cash Flow (Quarter)
320.07M-170.94M-99.68M-71.42M-16.86M-89.43M7.24M-14.13M114.95M61.84M-140.57M-20.00M7.78M-33.12M6.70M14.73M-21.63M24.77M-63.39M30.59M